An open label, randomized, phase II study of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer

Trial Profile

An open label, randomized, phase II study of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2009

At a glance

  • Drugs Docetaxel; Vadimezan
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top